Objective: To evaluate the use of elderly donors in liver transplantation (LT) and identify risk factors associated with a worse outcome. Summary Background Data: Use of livers from very old donors could expand the donor pool but is not universally implemented. Methods: This is a retrospective, single-center medical record review. From January 2001 to December 2014, 1354 LTs were performed. After exclusion of donors <18 years, ABO-incompatible LT, re-LT and UNOS 1 status patients, LT recipients were stratified into 2 groups based on donor age: 18-69 (n¼692) vs. !70 years (n¼515) then matched using a propensity score approach. Two groups were finally matched (young group ¼ 448 cases; old group ¼ 515 cases). Results: The median (interquartile range [IQR]) follow-up was 5.0 (2.0-8.4) years. Comparing the 2 identified groups, no differences were observed regarding early retransplants (1.8 vs. 2.9; P ¼ 0.3), HCV-related death (7.6 vs. 8.7%; P ¼ 0.6), vascular (5.8 vs. 5.0%; P ¼ 0.7), and biliary complications (16.5 vs. 18.6%; P ¼ 0.4). On multivariate analysis, independent risk factors for graft loss were: HCV-positive recipient (HR ¼ 2.1; 95% CI ¼ 1.6-2.7; P < 0.001), donor age (HR ¼ 1.0; 95% CI ¼ 1.0-1.0; P < 0.001), cold ischemia time (HR ¼ 1.0; 95% CI ¼ 1.0-1.0; P ¼ 0.042), and donor history of diabetes mellitus (HR ¼ 1.48; 95% CI ¼ 1.03-2.13; P ¼ 0.036). Conclusions: Use of elderly donors is not associated per se with an increased risk of vascular and biliary complications. In the presence of cold ischemia time and diabetes mellitus, appropriate donor-to-recipient matching is warranted.
T he use of livers from very old donors offers a means to expand the donor pool in liver transplantation (LT), but this practice is not universally implemented due to concerns about short-and long-term complications, 1 especially in hepatitis C virus (HCV)-positive recipients. 2 The factors associated with improved graft and patient survival rates have not been clearly recognized, and data on the incidence of biliary and hepatic artery complications are conflicting. [3] [4] [5] Although donor age has progressively increased in recent years, transplantation of elderly liver grafts is still limited. 6 Recent studies have shown that old donors may provide similar outcomes compared with younger ones when careful selection and appropriate donor and recipient management strategies are adopted, and when donor age is not associated with additional risk factors for poor graft outcome. 7 Strategies for accurate donor graft evaluation, selection, and allocation, as well as management of elderly livers before and after procurement, might help to increase the number of transplants while maintaining favorable long-term graft and patient survival. In order to advance our understanding of the outcome of LT using elderly grafts, we retrospectively compared 2 matched cohorts of recipients stratified by donor graft age (younger vs. older), to evaluate medical and surgical posttransplant complications and risk factors associated with worse outcomes.
METHODS

Study Design and Setting
This is an institutional review board (IRB)-approved, singlecenter, retrospective analysis of all deceased-donor LTs performed at the University of Pisa Medical School Hospital between January 2001 and December 2014. During this period, a total of 1354 LTs were performed. Of these, 33 (2.4%) received a graft from donors <18 years; 169 (12.5%) from donors aged 18 to 39 years; 609 (45.0%) from donors aged 40 to 69 years, and 543 (40.1%) from donors !70 years. Donors younger than 18 years (n ¼ 33), ABOincompatible LT (n ¼ 24), United Network for Organ Sharing (UNOS) status 1 recipients (n ¼ 34), and re-LT (n ¼ 56) were excluded from the analysis. Thus, 1207 patients were included and divided into 2 groups: those receiving younger grafts (YG group, donor 18-69 yrs; n ¼ 692) versus those receiving older grafts (OG group, donor !70-yrs; n ¼ 515).
To minimize possible confounders for the risk of graft loss, we matched the 2 groups using propensity score matching (PSM). After PSM, YG group presented a numerosity of 448 cases, while OG group reported a numerosity of 515 cases.
The overall median follow-up for the investigated population after PSM was 5.0 years (interquartile range (IQR) ¼ 2.0-8.4).
Donor Evaluation
Deceased-donor data were obtained from clinical charts. Eligibility for LT was evaluated as per our institutional policy and according to the Italian National Transplant Agency (Centro Nazionale Trapianti, CNT) guidelines. 8 The variables examined were: age; sex; body weight; height; body mass index (BMI); cause of death; liver function tests at procurement; comorbidities (type 2 diabetes mellitus [DM2], hypertension, cardiovascular disease, renal disease, and dyslipidemia); use of inotropic agents and serologic status with regard to hepatitis B virus (HBV) and HCV infection. Donors were classified as having diabetes mellitus, hypertension, or dyslipidemia if they were receiving relevant medication at the time of procurement, and were classified as having renal disease if they had undergone renal replacement treatment, irrespective of the onset date. Donors with a history of cardiac disease or cardiac surgery were considered cardiopathic. Donor hemodynamic instability was defined as any episode of cardiac arrest and/or severe hypotension (mean arterial pressure <60 mm Hg) for more than 1 hour during the intensive care unit (ICU) stay. The vasoactive-inotropic score (VAS) was calculated according to the formula: 9 dopamine ðmcg=Kg=min Â 100Þ þ noradrenaline ðmcg=Kg=min Â 100Þ þ adrenaline ðmcg=Kg=min Â 100Þ þ dobutamine ðmcg=Kg=min Â 100Þ þ vasopressin ðmcg=Kg=min Â 100Þ and was based on the inotrope doses reported within the last 24 h before organ procurement.
A liver graft biopsy was performed on demand, depending on surgical evaluation at procurement. All biopsies were reviewed at the University of Pisa Institute of Pathology. A graft was discarded if any of the following were present: macrovesicular steatosis >30%; necrosis >5%; fibrosis !2 according to the Ishak score; 10 severe microangiopathy (i.e., arteriolar thickening >60%) and macroangiopathy with no possibility of performing arterial anastomosis, unless otherwise indicated by the recipient's clinical status. Additionally, fibrosis stage 1 as per Ishak10; 1 to 5% necrosis; 10 to 30% macrosteatosis; 30 to 60% arterial wall thickening, and a moderate portal inflammatory infiltrate were considered risk factors, and a graft was discarded if !3 of these were present.
Recipients
All LT recipients were evaluated in the pretransplant outpatient clinic or wards and followed up after transplantation according to our institutional policies. Data collected for the current analysis were: age at transplant; sex; body weight; height; BMI; donor-to-recipient sex mismatch; indication for LT; pre-LT biological MELD score; donor age Â recipient MELD (D-MELD); 11 post-LT surgical complications (type and severity according to the modified Clavien classification system); 12 biopsy-proven acute rejection and graft and patient survival. Patient and graft survival and post-LT complications were censored at the time of event or as of December 31, 2015. Graft failure was defined as need for re-LT, and was censored at the time of relisting at our center or elsewhere. A severe vascular complication was any posttransplant abnormality in hepatic artery, portal vein, or vena cava associated with symptoms or signs and requiring a radiological or surgical procedure. Posttransplant biliary complication was any abnormality in the biliary tree associated with symptoms or signs and requiring an endoscopic or surgical procedure. Ischemic-type biliary lesion (ITBL) was any donor biliary tract with nonanastomotic stenosis requiring an endoscopic or radiological procedure in the absence of vascular complications. Primary nonfunction (PNF) was defined as patient death or need for retransplantation within 1 week after LT, excluding technical complications. Primary dysfunction (PDF) was defined as patient death or need for re-LT> 1 week but <6 months, excluding technical complications. If PDF was further complicated by fatal infection, the case was still categorized as PDF.
Immunosuppression was based on calcineurin inhibitors (CNI) in all patients. Immunosuppressive protocols for patients included in the current analysis varied according to era and availability of drugs, but outside clinical study trials we mainly employed cyclosporine A for HCV-positive recipients and tacrolimus for non-HCV-positive patients, combined with antimetabolites (mycophenolic acid), steroids and/or induction with an anti-CD25 agent for patients requiring delayed or minimized CNI introduction.
Surgery
Donors were procured with aortic flush only, using Celsior solution (Genzyme-Sanofi, Milan, Italy), and en bloc liver and pancreas procurement, as previously described, 13 until April 2013. After that date, a dual perfusion (portal and aortic) technique with Celsior solution was applied. All LT procedures were performed using the conventional technique with vena cava replacement and veno-venous bypass. A T-tube was routinely used for duct-to-duct biliary anastomosis and removed 3 months after transplantation. Variables included in the current analysis were: cold ischemia time (CIT) and duration of the anhepatic phase.
Graft Allocation Policy
Before implementation of a consensus-based allocation model in June 2015, 14 no national liver graft algorithm existed in Italy except for UNOS status 1 patient, pediatric recipients, and patients with MELD scores !30 who were granted national priority. Beyond these indications, grafts were allocated within the region of origin based on center-based algorithms. Until 2005, grafts at our center were allocated to adult recipients based on UNOS categories for non-HCC patients and on tumor stage for HCC.
In 2005 we implemented a MELD-based allocation algorithm for adult transplantation whereby liver grafts from donors 3<80 years were allocated following this rank: retransplants (irrespective of MELD score); combined liver-kidney transplantations (irrespective of MELD score); patients with MELD scores of 15 to 30 according to their scores. T3-HCC patients received a MELD exception score of 25, and T2-HCC patients an exception score of 22. Further exceptions to MELD scores were according to international guidelines published elsewhere. 15 
Statistical Analysis
Continuous variables were reported as medians and IQR. Categorical variables were reported as numbers and frequencies. Comparisons between the groups before and after PSM were made using Fisher exact text for categorical variables, and Student t test for continuous variables.
To compensate for the nonrandomized design of this retrospective study, a PSM was computed using a multivariate logistic regression model with donor age (18-69 vs. !70 yrs) as the dependent variable.
The PSM was rigorously constructed and implemented according to expert statisticians guidelines. 16 Sixteen possible confounders for the risk of graft loss were used as covariates: recipient male sex, recipient HCV-positive status, recipient HBV-positive status, alcohol-related cirrhosis as main cause of LT, biliary cirrhosis as main cause of LT, donor male sex, donor BMI, blunt trauma as cause of donor death, donor sGOT peak, donor sGPT peak, donor Na peak, VAS, donor hemodynamic instability, donor cardiac arrest, local organ procurement, and cold ischemia time. All these variables were selected according to their potential correlation with the risk of graft loss. Assessment of matching quality was performed comparing the 2 groups before and after PSM using a 2-sample t test, with the intent to check if significant differences in covariate means remained after the matching.
Unfortunately, no other pre-LT recipient-related clinical variables associated with a more severe illness (i.e., UNOS1 status, pre-LT need for mechanical ventilation, pre-LT hemodialysis or pre-LT use of vasoactive drugs) were included in the model due to their rarity in the present series: all the cases of re-LT and LT for fulminant hepatitis were in fact preliminarily removed from the initially investigated population with the intent to avoid possible selection biases.
Moreover, age-specific donor variables (i.e., age-related comorbidities like DM2 and hypertension) and variables directly connected with age-driven graft allocation matching (i.e., recipient age, presence of HCC and last MELD value at LT) were not used for constructing the PSM model due to their strong connection with donor age.
PSM was performed using a nearest-neighbor matching algorithm, which attempted to match each patient in the OG with a patient from the YG based on the closest propensity score, with a difference <10% of the standard deviation of the scores. Unpaired patients were discarded from analysis.
After PSM, a multivariate Cox proportional hazard model was used to explore the prognostic value for the risk of graft loss in the selected population. Twenty-seven preoperative donor, recipient, and transplant-related variables were tested. A stepwise backward conditional procedure was used, with variables having a P value >0.1 removed from the final model. Hazard ratios (HR) and 95% confidence intervals (CI) were reported for significant variables. Variables were considered statistically significant if P value was <0.05. Graft survival rates were assessed using Kaplan-Meier statistics and the log rank test. SPSS statistical package version 23.0 was used (SPSS Inc, Chicago, IL).
RESULTS
Before PSM, several differences were observable comparing YG and OG groups. Table 1 reports recipient-, donor-, and transplant-related characteristics in the 2 groups before PSM. HCC and HBV-positivity was more common in patients receiving older grafts (P < 0.001 and 0.01, respectively), with more cases of donors deceased due to cerebrovascular accident (83.3 vs. 64.9%; P < 0.001) and a higher number of donors with DM2 and hypertension (both P < 0.001). YG cases more commonly received grafts coming from local donors (23.8 vs. 17.5%; P ¼ 0.008) and with previous cardiac attack (9.5 vs. 4.3%; P < 0.001). Median CIT was longer in YG cases (475 vs. 455 minutes; P ¼ 0.01).
As previously reported, after PSM the number of cases observable in the YG group passed from 692 to 448 patients, while the numerosity of OG group remained the same (n ¼ 515). Table 2 reports recipient-, donor-, and transplant-related characteristics in the 2 groups after PSM. All the variables used for the construction of the PSM that were statistically different before PSM lost their significance after the matching. For example, recipient-specific variables like sex and underlying liver disease (i.e., HCV, HBV, alcohol-related cirrhosis, and biliary cirrhosis) were not different between the two groups. Similarly, donor characteristics like BMI, traumatic cause of death, VAS, hemodynamic instability, cardiac arrest, local procurement, peaks of sGOT, sGPT, and Na were similar. Finally, also CIT was not statistically significant between the groups.
However, despite the rigorous construction of the PSM, some differences remained between the groups. For example, recipient age (P < 0.001), HCC as indication for LT (P < 0.001) and MELD score (P ¼ 0.02) all were statistically different, as a consequence of the agerelated matching. In fact, aged grafts were preferentially allocated to aged recipients more commonly presenting lower MELD scores or HCC as indication for LT. With regards to donor characteristics, cerebrovascular accident (CVA) was more frequent in the OG group (83.3 vs. 77.7%; P ¼ 0.03). Also, arterial hypertension (60.2 vs. 40.2%; P < 0.001), DM2 (12.8 vs. 7.6%; P ¼ 0.008), and cardiopathy (34.8 vs. 18.8%; P < 0.001) were more frequent in the OG group.
Re-LT and Post-LT Complications
No differences were observed between groups in relation to early (within 30 days) re-LT rate (1.8% vs. 2.9%; P ¼ 0.3), incidence of PNF/PDF (4.2 vs. 5.4%; P ¼ 0.5), and HCV-related death (7.6% vs. 8.7%; P ¼ 0.6). A higher number of PNF/PDF-related re-LTs (0.7% vs. 2.5%; P ¼ 0.04) was observed in the OG, also explaining the increased number of overall re-LT observable in this group (2.7 vs. 5.2%; P ¼ 0.049). Rates of vascular (5.8% vs 5.0%; P ¼ 0.7) and biliary (16.5% vs. 18.6%, P ¼ 0.4) complications were similar (Table 3) .
Graft Loss
The overall number of graft losses was 262 of 963 (27.2%), comprising 146 of 515 (28.3%) in the OG and 116 of 448 (25.9%) in CI indicates confidence intervals; CVA, cerebrovascular accident; DM2, diabetes mellitus type 2; HCC, hepatocellular cancer; HR, hazard ratio; MELD, model for endstage liver disease; sGOT, serum glutamic oxaloacetic transaminase; sGPT, serum glutamic pyruvic transaminase.
the YG (P ¼ 0.4). As reported in Table 4 , no differences were observed between the two groups with regards to causes of graft loss.
Risk Factors for Graft Loss
A Cox regression analysis was performed on the post-PSM population with the intent to investigate the risk factors for graft loss. The analysis identified 4 independent risk factors: recipient HCVpositivity (HR ¼ 2.1; 95% CI ¼ 1.6-2.7; P < 0.001), donor age (HR ¼ 1.0; 95% CI ¼ 1.0-1.0; P < 0.001), CIT (HR ¼ 1.0; 95% CI ¼ 1.0-1.0; P ¼ 0.042), and donor DM2 status (HR ¼ 1.5; 95% CI ¼ 1.0-2.1; P ¼ 0.047) ( Table 5 ).
Graft Survival According to Risk Factors
Stratifying YG and OG patients according to the presence or absence of the risk factors donor DM2 positivity and/or CIT ! 8 hours, 4 different groups were defined. Analyzing the post-PSM overall study population, OG patients with risk factors showed worse graft survival rates when compared with all the other groups. Specifically, OG patients with risk factors had 5-year graft survivals of 69.9 versus 77.2% of OG patients without risk factors (P ¼ 0.01). Interestingly, OG patients without risk factors had similar survivals when compared with YG cases with or without risk factors (in both cases, P ¼ 0.4).
When the entire population was dichotomized according to the recipient HCV status, in the specific setting of HCV-negativity no statistically significant differences were observed comparing all the four groups. Interestingly, OG recipients with risk factors showed lower 5-year graft survival rates (80.7%), despite this difference never reached statistical relevance when compared with the other groups.
Graft survival was inferior for HCV-positive recipients across all strata. However, this was further exacerbated by the presence of additional risk factors: OG recipients with risk factors had the worse results (5-yr survival rates: 60.4%), in all the cases statistically inferior when compared with the other groups. Interestingly, OG HCV-positive recipients with no risk factors showed comparable graft survival to YG HCV-positive recipients who had risk factors (P ¼ 0.1) ( Table 6 and Fig. 1 ). 
DISCUSSION
Use of old donors for LT is challenging but could increase the global pool of available grafts. However, such a strategy has been criticized due to the potential for inferior outcomes. 17, 18 Nevertheless, several single-center studies have shown that use of grafts from well-selected populations of elderly donors can achieve results which are comparable to those with younger grafts. 19, 20 The present study identified 4 predictors of graft loss: donor age; CIT; donor diabetes, and recipient HCV status. All the donorspecific characteristics have already been observed in previous studies. 18, 21 It has been largely demonstrated that CIT increases the risk of ischemia-reperfusion injury, initial graft dysfunction, 22 and posttransplant biliary complications 23 . Grafts presenting very long CIT (>12 h) were uncommonly used in the present experience: however, it may be speculated that the evolutive nature of ischemic damages is not properly assessed by biopsy and different ways of graft evaluation and ischemia/reperfusion damage minimization, such as normothermic perfusion machine preservation, should be evaluated.
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DM2 has been already investigated as a detrimental parameter for liver function as well. DM2 favors macrovesicular steatosis, a well-known risk factor for graft loss, 25 and even biliary complications. 26 A role for diabetes in impairing liver microvascular circulation has been reported, 27 ,28 which might be aggravated by age-related microvascular thickening and sinusoidal pseudo-capillarization. 29, 30 Age, ischemia, and diabetes-related vascular injuries can account for the increased vulnerability of older grafts to ischemia/reperfusion injury. 31 Identification of histological markers of diabetes-related liver injuries (e.g. vascular thickness), and their correlation with worse clinical outcomes, could be of great interest in the future. 32 Our data suggest that the combination of specific donor-, recipient-, and transplant-related risk factors more than the single presence of one of them can favor a negative post-LT course. In other terms, not all the old grafts are per se responsible for poor results, but only a subgroup of them presenting multiple detrimental characteristics. This aspect is well demonstrated in the masterpiece study from Feng et al, in which the so-called Donor Risk Index (DRI) was derived from the combination of different donors' features. 18 If DRI and other donor-specific scores 21 can predict the risk of graft loss, recipient-related risk factors also play a fundamental role in post-LT outcomes. In the present study, recipient HCV-positive status was the main risk factor for graft loss. As a consequence, a more refined ''tailoring'' in the matching between a ''marginal'' donor and a ''marginal'' recipient represents the goal to obtain, with the intent to minimize the risks related to an inappropriate allocation. Many studies have already shown that the combination ''HCV-positive recipient-marginal donor'' is related to worse results. Malouf et al 33 investigated the impact of DRI on the outcome of HCV-positive recipients and showed that a higher DRI was associated with a statistically significant increase in the relative risk of graft failure and patient death. This was confirmed in a multicenter Italian study showing that a lower value for donor age Â MELD score (D-MELD) was associated with a reduced risk for graft loss. 34 The authors demonstrated that better outcomes were obtained when transplanting older grafts into lower MELD recipients or by the use of younger grafts in more severely ill patients, as indicated by higher MELD scores. 35 Our experience supports these findings, with the additional merit of a methodological approach (i.e., PSM) for comparison of the 2 patient cohorts. Based on our study, after removing possible confounders for the risk of graft loss, use of elderly grafts was not associated with an increased risk of HCV-related death, overall graft dysfunction, vascular or biliary complications.
For HCV-positive recipients, younger grafts with no risk factors achieved the best survival rates. However, recipients of older grafts without risk factors achieved similar survivals with respect to younger grafts having risk factors, highlighting that these predictors were more important than donor age in determining the posttransplant outcome. This scenario will change in the near future with the advent of the novel direct-acting antiviral agents. 35 Interestingly, HCV-negative recipients of either young or old grafts showed similar results, irrespective of the presence of risk factors. This observation suggests that outcomes are comparable with FIGURE 1. Graft survival in HCVnegative and HCV-positive recipients stratified according to donor age and the presence of risk factors (cold ischemia time and/or diabetes mellitus).
older or younger donors, even in the presence of risk factors, in a HCV-negative setting. For HCV-positive patients, transplantation with older grafts with risk factors resulted in poorer long-term results. However, the presence of risk factors warrants careful evaluation also in the case of younger donors. The evidence that old grafts without risk factors present similar survivals when compared with young ones with risk factors should be in fact explained by the fact that additional injuries of acute (i.e., necrosis) or chronic (i.e., macro-steatosis and vascular thickening) etiologies may produce unfavorable results after LT also using younger grafts.
Thanks to the recent introduction of effective antiviral medication, old donor grafts should be considered an effective resource for HCV-positive recipients, minimizing the use of grafts with additional multiple risk factors.
We honestly admit that, despite the rigorous statistical approach used for constructing the present model, a ''perfect'' matching was impossible to be obtained comparing a young versus an old donor: in fact, several age-and donor-to-recipient matchrelated variables were impossible to be normalized after PSM. However, our intent was not to construct a model in which ''the perfect'' aged donor should be compared with a young one: such a model is in fact substantially unrealistic and not useful from the clinical point of view. Our intent was instead to minimize the potential effect of not-age-related confounders, with the intent to observe in the ''real'' clinical practice the possibility to use for LT an aged donor with his comorbidities.
CONCLUSIONS
Use of older donors for LT is not associated with an increased incidence of vascular or biliary complications and only a slightly higher rate of retransplantation due to graft dysfunction. The presence of risk factors, notably donor diabetes and cold ischemia time, resulted in worse results for elderly donor grafts transplanted into HCV-positive recipients. However, these risk factors adversely impacted posttransplant survival even in younger grafts. Older grafts without risk factors provided excellent long-term graft survival rates, especially for HCV-negative recipients.
